FILE - In this March 2020 photo provided by Gilead Sciences, a vial of the investigational drug remdesivir is visually inspected at a Gilead manufacturing site in the United States. (Gilead Sciences via AP)

Health Canada approves remdesivir for treatment of severe COVID-19

First drug authorized by the agency to treat the virus

Health Canada has authorized the use of drug remdesivir to treat severe symptoms of COVID-19, the agency said Tuesday (July 28).

The antiviral drug, manufactured by Gilead Sciences Canada, Inc., is the first treatment authorized for patients with serious symptoms of the virus in Canada. The drug is currently only approved for use in adults and teens aged 12 and up with a weight of at least 40 kilograms. It is not authorized for use in children or pregnant women, and is administered intravenously to treat patients with pneumonia requiring supplemental oxygen.

Canada is not the first to approve the use of remdesivir for COVID-19; the drug has been approved for use in U.S., Europe, Japan, Singapore and Australia. So far, the agency said a “small number” of patients are being treated with the drug under the Special Access Program, which will not be required for new patients going forward.

Health Canada said it completed an expedited six-week review to determine the drug’s benefits outweigh its risks when it comes to COVID-19. Two existing clinical trials are ongoing to evaluate the safety and efficacy of remdesivir. According to the European Medicines Agency, the most common side effect in healthy volunteers are increased blood levels of liver enzymes, and nausea in COVID-19 patients.

ALSO READ: B.C. sets limits on number of guests, visitors in vacation rentals, houseboats

ALSO READ: B.C. records 81 more cases of COVID-19 in B.C. in three days


@katslepian

katya.slepian@bpdigital.ca

Like us on Facebook and follow us on Twitter.

Want to support local journalism during the pandemic? Make a donation here.

Coronavirus

Get local stories you won't find anywhere else right to your inbox.
Sign up here

Just Posted

Barriere RCMP are asking, “Do you know who these people are?”

RCMP are hoping someone will recognize the people in these photos who… Continue reading

Barriere RCMP looking for alleged AG Foods shoplifter

RCMP are requesting help in identifying a woman who departed the AG… Continue reading

Valley Voices From The Past: Early policing in the North Thompson Valley

By Nelson Hindle The following is an excerpt from Upper North Thompson… Continue reading

Welcoming the hot weather with a trip to the Splash Pad

The final arrival of scorching temperatures these past few weeks, with Barriere… Continue reading

District of Barriere Utilities Manager reports to council on Barriere wells

District of Barriere Utilities Manager Ian Crosson presented a verbal report during… Continue reading

Lawsuit launched after Florida child handcuffed, booked and briefly jailed

Suit alleges “deliberate indifference” to what should have been handled as a behavioural issue

Russia approves vaccine, Putin hopes to begin mass production

Critic calls decision to proceed without thorough testing ‘dangerous and grossly immoral’

Man, 54, charged in connection with fatal attack of Red Deer doctor

Doctor was killed in his walk-in clinic on Monday

Doctor slain in Alberta medical clinic was devoted father, husband

Red Deer doctors on edge after attack on colleague who had two young daughters

Royal B.C. Museum wants B.C.’s COVID-19 nature observations

COVID-19 Collecting For Our Time: ongoing project cataloguing province’s pandemic experience

Feds offer ‘life preserver’ funds to BC Ferries as pandemic sinks revenue

For every dollar the province spends the federal government will match

Bad behaviour at B.C. restaurants ignites campaign calling for respect

“If you can’t follow the rules, then stay home,” says BC Restaurant and Foodservices Association

Over half of Americans oppose Trump tariff on Canadian aluminum: survey

The survey was conducted Aug. 7 to 9 among 1,513 Canadians and 1,003 Americans

Most Read